Long Acting Therapies Will Revolutionize Hemophilia Treatment
A ZoomRx pilot study with 35 Hematologists.
Treating physicians anxiously await long acting therapies (LAT).
Current Unmet Needs
Current Therapies Are Inconvenient
have convenience issues
"Effective but difficult to administer, induce inhibitors, short half life."
"Convenience needs to be improved. Current treatment requires frequent administration."
"Current therapies requires multiple administration, half life is too short & inconvenient."
LAT Will Greatly Improve Convenience Without Sacrificing Efficacy & Safety
"By decreasing the frequency. It will improve compliance."
"It would be a major breakthrough & will take market share."
Cost & Insurance Coverage May Slow LAT Rapid Adoption
are concerned about cost / insurance issues
"Insurance approval, possibility of anaphylaxis or increase in rate of allergic reactions."
"Cost would be the biggest barrier and insurance companies may not provide payments for these newer agents."
"Drugs will likely be priced prohibitively expensive and require an extensive authorization process."